Literature DB >> 16957639

Reduced burden of bacterial airway colonization with a novel silver-coated endotracheal tube in a randomized multiple-center feasibility study.

Jordi Rello1, Marin Kollef, Emili Diaz, Albert Sandiumenge, Yolanda del Castillo, Xavier Corbella, Regina Zachskorn.   

Abstract

OBJECTIVE: To assess the feasibility and safety of the respiratory infection control (RIC) device, a silver-coated endotracheal tube, and its effect on bacterial burden in the airways.
DESIGN: Prospective, randomized, single-blind, multiple-center study.
SETTING: Three hospitals in Spain and one in the United States. PATIENTS: Patients were eligible adults who required mechanical ventilation for > or =24 hrs and did not have respiratory infections. One hundred forty-nine patients were intubated and analyzed for safety; 121 were intubated > or =24 hrs and analyzed for tube colonization; 67 had negative baseline quantitative endotracheal aspirates and were analyzed for quantitative endotracheal aspirates colonization.
INTERVENTIONS: Intubation with the RIC device or a control endotracheal tube.
MEASUREMENTS AND MAIN RESULTS: The RIC device was associated with delayed colonization on the tube compared with the control device at the threshold of ++, +++, or > or =10(4) colony-forming units/mL (p = .02, log-rank test; p = .10, Wilcoxon's test) and in quantitative endotracheal aspirates at > or =10(6) colony-forming units/mL (p = .08, log-rank test; p = .05, Wilcoxon's test). The RIC device was associated with reduced colonization rate by days on the tube (p = .04, Wilcoxon's test) and in quantitative endotracheal aspirates (p = .05, Wilcoxon's test) at the same thresholds. The RIC device was associated with lower maximal bacterial burden in tracheal aspirates for 7 days (mean log-transformed burden, 4.2 +/- 2.3 vs. 5.5 +/- 1.7 log colony-forming units/mL; p = .02, Wilcoxon's test). Other between-group differences favored the RIC device but were not significant. Five adverse events were considered device related, including three events in the RIC group and two events in the control group.
CONCLUSIONS: In this prospectively planned, preliminary analysis, the RIC device was feasible and well tolerated. Larger studies are needed to determine whether delayed colonization, reduced colonization rate, and decreased bacterial burden will decrease the incidence of ventilator-associated pneumonia.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16957639     DOI: 10.1097/01.CCM.0000242154.49632.B0

Source DB:  PubMed          Journal:  Crit Care Med        ISSN: 0090-3493            Impact factor:   7.598


  19 in total

1.  Prevention of VAP: the whole is more than the sum of its parts.

Authors:  Thiago Lisboa; Marin H Kollef; Jordi Rello
Journal:  Intensive Care Med       Date:  2008-04-17       Impact factor: 17.440

2.  A 2015 Update on Ventilator-Associated Pneumonia: New Insights on Its Prevention, Diagnosis, and Treatment.

Authors:  Braden Waters; John Muscedere
Journal:  Curr Infect Dis Rep       Date:  2015-08       Impact factor: 3.725

Review 3.  Technologic advances in endotracheal tubes for prevention of ventilator-associated pneumonia.

Authors:  Juan F Fernandez; Stephanie M Levine; Marcos I Restrepo
Journal:  Chest       Date:  2012-07       Impact factor: 9.410

4.  Antibacterial Biomimetic Hybrid Films.

Authors:  M Carme Coll Ferrer; Noreen J Hickok; David M Eckmann; Russell J Composto
Journal:  Soft Matter       Date:  2013-02-28       Impact factor: 3.679

5.  Avoiding ventilator-associated pneumonia: Curcumin-functionalized endotracheal tube and photodynamic action.

Authors:  Amanda C Zangirolami; Lucas D Dias; Kate C Blanco; Carolina S Vinagreiro; Natalia M Inada; Luis G Arnaut; Mariette M Pereira; Vanderlei S Bagnato
Journal:  Proc Natl Acad Sci U S A       Date:  2020-08-31       Impact factor: 11.205

6.  Bactericidal effects of silver plus titanium dioxide-coated endotracheal tubes on Pseudomonas aeruginosa and Staphylococcus aureus.

Authors:  Keiko M Tarquinio; Nikhil K Kothurkar; Dharendra Y Goswami; Ronald C Sanders; Arno L Zaritsky; Ann Marie LeVine
Journal:  Int J Nanomedicine       Date:  2010-04-07

Review 7.  Use of silver in the prevention and treatment of infections: silver review.

Authors:  Amani D Politano; Kristin T Campbell; Laura H Rosenberger; Robert G Sawyer
Journal:  Surg Infect (Larchmt)       Date:  2013-02-28       Impact factor: 2.150

8.  In vitro and murine efficacy and toxicity studies of nebulized SCC1, a methylated caffeine-silver(I) complex, for treatment of pulmonary infections.

Authors:  Carolyn L Cannon; Lisa A Hogue; Ravy K Vajravelu; George H Capps; Aida Ibricevic; Khadijah M Hindi; Aysegul Kascatan-Nebioglu; Michael J Walter; Steven L Brody; Wiley J Youngs
Journal:  Antimicrob Agents Chemother       Date:  2009-05-18       Impact factor: 5.191

9.  The antimicrobial effect of Octenidine-dihydrochloride coated polymer tracheotomy tubes on Staphylococcus aureus and Pseudomonas aeruginosa colonisation.

Authors:  Michaela Zumtobel; Ojan Assadian; Matthias Leonhard; Maria Stadler; Berit Schneider
Journal:  BMC Microbiol       Date:  2009-07-25       Impact factor: 3.605

10.  Use of the probiotic Lactobacillus plantarum 299 to reduce pathogenic bacteria in the oropharynx of intubated patients: a randomised controlled open pilot study.

Authors:  Bengt Klarin; Göran Molin; Bengt Jeppsson; Anders Larsson
Journal:  Crit Care       Date:  2008-11-06       Impact factor: 9.097

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.